Abstract
In a randomized study, two oral medications, ketotifen and montelukast, were compared for children with mild persistent asthma. Montelukast revealed faster clinical responses than ketotifen, showing improved exhaled nitric oxide, peak expiratory flow, and asthma scores in 1 wk. After 8-wk of medication, both ketotifen and montelukast revealed improved clinical responses. However, 8 wk of ketotifen, but not montelukast, decreased plasma serum thymus and activation-regulated chemokine (317.854 +/- 207.906 vs. 181.348 +/- 167.109, p < 0.05), macrophage-derived chemokine (355.11 +/- 174.30 vs. 169.19 +/- 62.42, p < 0.05) levels. In conclusion, different oral non-steroidal anti-inflammatory drugs revealed faster or slower treatment responses due to different mechanisms.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Acetates / pharmacology
-
Acetates / therapeutic use*
-
Anti-Asthmatic Agents / pharmacology
-
Anti-Asthmatic Agents / therapeutic use*
-
Asthma / drug therapy*
-
Asthma / immunology*
-
Chemokine CCL17
-
Chemokine CCL22
-
Chemokines / blood*
-
Chemokines, CC / blood
-
Child
-
Cyclopropanes
-
Double-Blind Method
-
Histamine H1 Antagonists / pharmacology
-
Histamine H1 Antagonists / therapeutic use*
-
Humans
-
Ketotifen / pharmacology
-
Ketotifen / therapeutic use*
-
Leukotriene Antagonists / pharmacology
-
Leukotriene Antagonists / therapeutic use*
-
Peak Expiratory Flow Rate
-
Quinolines / pharmacology
-
Quinolines / therapeutic use*
-
Respiratory Function Tests
-
Sulfides
-
Th2 Cells / immunology
Substances
-
Acetates
-
Anti-Asthmatic Agents
-
CCL17 protein, human
-
CCL22 protein, human
-
Chemokine CCL17
-
Chemokine CCL22
-
Chemokines
-
Chemokines, CC
-
Cyclopropanes
-
Histamine H1 Antagonists
-
Leukotriene Antagonists
-
Quinolines
-
Sulfides
-
montelukast
-
Ketotifen